Conference Call & Webcast
Thursday, November 13, 2014 at 8:30 a.m. EST/5:30 a.m. PST
Domestic: 888-438-5525
International: 719-457-2083
Conference ID: 5950362
Webcast: http://public.viavid.com/index.php?id=111791
Replays – Available through November 27, 2014
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 5950362
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
Media: Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., Phone: (646) 666-3188, info@brainstorm-cell.com, or Investors: Michael Rice, LifeSci Advisors, LLC, Phone: 646-597-6979, mrice@lifesciadvisors.com